Glaxosmithkline LLC

Glaxo Wellcome Spa

Emiliangelo Ratti

Giovanni Gaviraghi

Daniele Andreotti

Luca Tarsi

Giovanna Tedesco

Tino Rossi

Stefano Biondi

David Gordon Trist

Domenica Antonia Pizzi

Aldo Feriani

Mauro Corsi

Gabriella Finizia

Isidore Faiferman

Emilio Merlo Pich

Paul Bryan Wren

Francesco Crespi

Angelo Mario Reggiani

The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.

Use of a p38 kinase inhibitor for treating psychiatric disorders

A compound of formula (I), salts and metabolically labile esters thereof, wherein R represents optionally substituted aryl or heteroaryl group; A represents a propylene chain or A is a chain of members one of which is selected from an oxygen or sulphur atom or the group NH or a substituted derivative thereof and the other two members are methylene groups, having antibacterial activity, processes for their preparation and to their use in medicine.

Tricyclic carbapenem compounds

The use of CCK-B antagonists for the treatment of sleep disorders.

Use of cck-b receptor antagonists for the treatment of sleep disorders

Growing community of inventors

Verona, Italy

Emiliangelo Ratti